top of page
Search

AINOSTICS secures $2,600,000

  • Writer: AINOSTICS
    AINOSTICS
  • Feb 7, 2022
  • 1 min read

We have just secured approximately $2,600,000 in funding to accelerate the development of our ground-breaking technologies for performing diagnosis and outcome prognosis in neurological conditions, such as dementia.


According to our CEO, Dr Hojjat Azadbakht: "this funding will be used to conduct pilot studies in a number of clinical sites in the UK and accelerate our NHS adoption strategy. It will also significantly de-risk the already unique proposition offered by AINOSTICS for future investors".


A big thank you to our fantastic team at AINOSTICS for their continued hard work, and to all our advisors and partners for sharing our vision.

More details to be revealed in the near future.



 
 
 

Comments


AIN_LOGO_BLK_Website.png
  • White LinkedIn Icon
  • X
  • Email-PNG-Pic-Recovered

 

               LONDON          MANCHESTER          SAN FRANCISCO 

AINOSTICS, IQ, AIN, BR[AI]N and their respective logos are trademarks of AINOSTICS Ltd in numerous territories.
 

AINOSTICS © 2025. All rights reserved | AINOSTICS Limited is a company registered in England. | Company Registration No. 11420367 | Privacy Statement

bottom of page